Scientists demonstrate potential for personalised cancer vaccine
Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard have created a personalised vaccine called NeoVax for the treatment of cancer. The technique targets specific neoantigen molecules of cancerous tumour cells and generates highly specific immune responses, which could help to provide a more tailored approach to the treatment of the disease. The proof-of-principle treatment was tested on melanoma patients and had negligible side-effects.

Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.